Theradiag Valuation
| ALTHE Stock | EUR 0.37 0.03 8.82% |
Theradiag seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Theradiag SA from inspecting the company fundamentals such as Shares Owned By Institutions of 7.88 %, shares outstanding of 28.8 M, and Return On Asset of -0.25 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Theradiag's price fluctuation is out of control at this time. Calculation of the real value of Theradiag SA is based on 3 months time horizon. Increasing Theradiag's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Theradiag's intrinsic value may or may not be the same as its current market price of 0.37, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.37 | Real 0.31 | Hype 0.37 | Naive 0.35 |
The intrinsic value of Theradiag's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Theradiag's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Theradiag SA helps investors to forecast how Theradiag stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Theradiag more accurately as focusing exclusively on Theradiag's fundamentals will not take into account other important factors: Theradiag Total Value Analysis
Theradiag SA is presently projected to have takeover price of 20.58 M with market capitalization of 20.16 M, debt of 2.05 M, and cash on hands of 938.86 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Theradiag fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
20.58 M | 20.16 M | 2.05 M | 938.86 K |
Theradiag Investor Information
About 23.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.19. Theradiag SA had not issued any dividends in recent years. The entity had 367:350 split on the 26th of July 2016. Based on the key indicators obtained from Theradiag's historical financial statements, Theradiag SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Theradiag Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Theradiag has an asset utilization ratio of 13.68 percent. This connotes that the Company is making €0.14 for each dollar of assets. An increasing asset utilization means that Theradiag SA is more efficient with each dollar of assets it utilizes for everyday operations.Theradiag Ownership Allocation
Theradiag SA shows a total of 28.8 Million outstanding shares. Theradiag SA maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Theradiag Profitability Analysis
The company reported the revenue of 1.48 M. Net Loss for the year was (3.76 M) with loss before overhead, payroll, taxes, and interest of (1.4 M).About Theradiag Valuation
The stock valuation mechanism determines Theradiag's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Theradiag SA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Theradiag. We calculate exposure to Theradiag's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Theradiag's related companies.Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners. The company was founded in 2004 and is based in Malakoff, France. THERACLION operates under Medical Devices classification in France and is traded on Paris Stock Exchange. It employs 22 people.
8 Steps to conduct Theradiag's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Theradiag's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Theradiag's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Theradiag's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Theradiag's revenue streams: Identify Theradiag's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Theradiag's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Theradiag's growth potential: Evaluate Theradiag's management, business model, and growth potential.
- Determine Theradiag's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Theradiag's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Theradiag Stock Analysis
When running Theradiag's price analysis, check to measure Theradiag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theradiag is operating at the current time. Most of Theradiag's value examination focuses on studying past and present price action to predict the probability of Theradiag's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theradiag's price. Additionally, you may evaluate how the addition of Theradiag to your portfolios can decrease your overall portfolio volatility.